Adrenosterone (androst-4-ene-3,11,17-trione, 11-oxoandrostenedione) is an endogenous steroid hormone that has been promoted as a dietary supplement capable of reducing body fat and increasing muscle mass. Adrenosterone has shown to be converted into 11-ketotestosterone in humans, which contributes to adrenosterone's androgenic effects. It is proposed that adrenosterone may function as an inhibitor of the 11beta-hydroxysteroid dehydrogenase type 1 enzyme (11beta-HSD1), which is primarily responsible for reactivation of cortisol from cortisone.

Andarine is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy. Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs. Andarine had been in phase I clinical trials by GTx for the treatment of cancer-related cachexia and osteoporosis. However, this research has been discontinued.

BMS-564929 is an investigational selective androgen receptor modulator, which is being developed by Bristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men ("andropause"). Bristol-Myers Squibb presented data for BMS 564929 that showed favorable pharmacokinetics and the potential for use at a very low dose (0.03mg).